Athira Pharma, Inc. (ATHA)

Market Cap	75.12M
Revenue (ttm)	n/a
Net Income (ttm)	-117.67M
Shares Out	38.33M
EPS (ttm)	-3.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	147,921
Open	2.000
Previous Close	1.960
Day's Range	1.940 - 2.050
52-Week Range	1.330 - 4.298
Beta	2.78
Analysts	Strong Buy
Price Target	12.00 (+512.25%)
Earnings Date	May 13, 2024

About ATHA

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 18, 2020
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: ATHA

Analyst Forecast

According to 2 analysts, the average rating for ATHA stock is "Strong Buy." The 12-month stock price forecast is $12.0, which is an increase of 512.25% from the latest price.

Price Target

$12.0

(512.25% upside)

Analyst Consensus: Strong Buy